Doxorubicin is established for the treatment of osteosarcomas and acts on a common mechanistic pathway with CD47 mAb by inducing immunogenic cell death (Apetoh et al., 2007; Casares et al., 2005). The gene discussed is CD47; the disease is osteosarcoma.